腺苷2A受体在实验性创伤性脑损伤中呈现时间依赖性双向神经保护作用
研究采用Wistar大鼠创伤性脑损伤模型,分假手术组、创伤性脑损伤组、腺苷2A受体激动剂CGS-21680组和拮抗剂SCH-58261组,在伤后15分钟及1、12、24小时评估。结果显示激动剂在伤后15分钟和1小时改善神经功能评分并降低环磷酸腺苷、白细胞介素-1β、氧化应激标志物、过氧化氢酶和半胱天冬酶-3水平,拮抗剂则在12和24小时显示保护作用。
要点
- 腺苷2A受体激动剂在创伤性脑损伤后15分钟和1小时改善神经功能评分。
- 腺苷2A受体拮抗剂在创伤性脑损伤后12和24小时改善神经功能评分。
- 腺苷2A受体激动剂和拮抗剂应根据创伤性脑损伤发生的时间点使用。
核心结论
- 腺苷2A受体激动剂在创伤性脑损伤早期阶段显示有益的神经保护作用,拮抗剂在后期阶段显示益处。
- 这些发现提示腺苷2A受体激动剂和拮抗剂应根据创伤性脑损伤发生的时间点使用。
研究设计与样本
- Wistar大鼠分为4个治疗组(假手术组、创伤性脑损伤组、腺苷2A受体激动剂CGS-21680组和腺苷2A受体拮抗剂SCH-58261组)和4个伤后时间点(15分钟及1、12、24小时)。
- 通过神经功能评分及环磷酸腺苷、白细胞介素-1β、氧化应激抗氧化标志物和半胱天冬酶-3水平检测腺苷2A受体激动剂和拮抗剂的效果。
主要发现
- 与创伤性脑损伤组相比,腺苷2A受体激动剂组在伤后15分钟和1小时神经功能评分显著改善,但在12和24小时未观察到改善。
- 腺苷2A受体拮抗剂组在伤后15分钟和1小时神经功能评分无改善,在12和24小时观察到显著改善。
- 腺苷2A受体激动剂在伤后15分钟和1小时对环磷酸腺苷、白细胞介素-1β、氧化应激标志物、过氧化氢酶和半胱天冬酶-3水平显示显著神经保护效应。
- 腺苷2A受体拮抗剂在这些时间点无效,但在伤后12和24小时显示保护效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Traumatic brain injury (TBI) results in both focal and diffuse brain pathological features that become severely exacerbated after the initial injury. Owing to this disease complexity, no effective therapeutic measure has yet been devised aimed directly at these pathological processes. We developed a clinically relevant model of TBI and tested the bidirectional neuroprotective role of adenosine 2A receptors (A2ARs) at different times. METHODS: Wistar rats were divided into 4 treatment groups (sham, TBI, A2AR agonist [CGS-21680], and A2AR antagonist [SCH-58261]) and 4 post-TBI intervals (15 minutes and 1, 12, and 24 hours). A2AR agonist and antagonist effects were tested by the neurological functional score (NFS) and levels of cyclic adenosine monophosphate, interleukin-1β, oxidative stress antioxidant markers, and caspase-3. RESULTS: The A2AR agonist-treated group showed significant NFS improvement at 15 minutes and 1 hour after TBI compared with the TBI group. However, no improvement was observed at 12 and 24 hours. The A2AR antagonists resulted in no NFS improvement at 15 minutes and 1 hour, and significant improvement observed at 12 and 24 hours. Significant neuroprotective effect with an A2AR agonist were observed with cyclic adenosine monophosphate, interleukin-1β, oxidative stress markers, catalase, and caspase-3 levels at 15 minutes and 1 hour after TBI. The A2AR antagonist showed no effect at these intervals but showed a protective effect at 12 and 24 hours after TBI. CONCLUSIONS: The A2AR agonist showed a beneficial neuroprotective effect at the early stages after TBI, and the A2AR antagonist showed a benefit at the later stages after TBI. These findings suggest that A2AR agonists and antagonists should be used in accordance with the point at which the TBI occurred.
引用
- Velayutham P, Murthy M, Babu KS, et al. Time-Dependent Bidirectional Neuroprotection by Adenosine 2A Receptor in Experimental Traumatic Brain Injury. World Neurosurg. 2019. PMID: 30735877. doi:10.1016/j.wneu.2019.01.164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。